The cellular ataxia telangiectasia-mutated kinase promotes epstein-barr virus lytic reactivation in response to multiple different types of lytic reactivation-inducing stimuli

Journal of Virology

Volumn 86, Issue 24, 2012, Pages 13360-13370

  Hagemeier, Stacy R ^a   Barlow, Elizabeth A ^a   Meng, Qiao ^a   Kenney, Shannon C ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; ATM PROTEIN; AZACITIDINE; BORTEZOMIB; HISTONE DEACETYLASE INHIBITOR; HYDROGEN PEROXIDE; IMMUNOGLOBULIN G ANTIBODY; NUTLIN 3; PROTEIN NA; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VIRUS PROTEIN; VPR PROTEIN;

ARTICLE; CELL LINE; CELL STRAIN AGS; CONTROLLED STUDY; DNA DAMAGE; DNA TRANSFECTION; EPSTEIN BARR VIRUS; GENE EXPRESSION; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STIMULUS RESPONSE; VIRUS GENOME; VIRUS INHIBITION; VIRUS REACTIVATION; VIRUS TITRATION; WESTERN BLOTTING; WILD TYPE;

BASE SEQUENCE; CELL CYCLE PROTEINS; CELL LINE; DNA PRIMERS; DNA-BINDING PROTEINS; HERPESVIRUS 4, HUMAN; HUMANS; IMIDAZOLES; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; PYRONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; VIRUS ACTIVATION;

ATAXIA TELANGIECTASIA; HUMAN HERPESVIRUS 4;

EID: 84870704593     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01850-12     Document Type: Article

References (102)

1. Adamson AL, Kenney S. 2001. Epstein-Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J. Virol. 75:2388-2399.
2. Adamson AL, Kenney SC. 1998. Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product. Virology 251:187-197.
3. Adler B, et al. 2002. Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1. Proc. Natl. Acad. Sci. U. S. A. 99:437-442.
4. Ben-Sasson SA, Klein G. 1981. Activation of the Epstein-Barr virus genome by 5-aza-cytidine in latently infected human lymphoid lines. Int. J. Cancer 28:131-135.
5. Bhatti S, et al. 2011. ATM protein kinase: the linchpin of cellular defenses to stress. Cell. Mol. Life Sci. 68:2977-3006.
6. Bhende PM, Seaman WT, Delecluse HJ, Kenney SC. 2005. BZLF1 activation of the methylated form of the BRLF1 immediate-early promoter is regulated by BZLF1 residue 186. J. Virol. 79:7338-7348.
7. Bieging KT, Amick AC, Longnecker R. 2009. Epstein-Barr virus LMP2A bypasses p53 inactivation in aMYCmodel of lymphomagenesis. Proc. Natl. Acad. Sci. U. S. A. 106:17945-17950.
8. Borza CM, Hutt-Fletcher LM. 2002. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat. Med. 8:594-599.
9. Bose S, et al. 2009. The ATM tumour suppressor gene is down-regulated in EBV-associated nasopharyngeal carcinoma. J. Pathol. 217:345-352.
10. Cai Q, et al. 2011. Epstein-Barr virus nuclear antigen 3C stabilizes Gemin3 to block p53-mediated apoptosis. PLoS Pathog. 7:e1002418. doi: 10.1371/journal.ppat.1002418.
11. Cann KL, Dellaire G. 2011. Heterochromatin and the DNA damage response: the need to relax. Biochem. Cell Biol. 89:45-60.
12. Chang PC, et al. 2009. Kruppel-associated box domain-associated protein-1 as a latency regulator for Kaposi's sarcoma-associated herpesvirus and its modulation by the viral protein kinase. Cancer Res. 69:5681-5689.
13. Chang SS, et al. 2008. Critical role of p53 in histone deacetylase inhibitor-induced Epstein-Barr virus Zta expression. J. Virol. 82:7745-7751.
14. Chen K, Albano A, Ho A, Keaney JF, Jr. 2003. Activation of p53 by oxidative stress involves platelet-derived growth factor-beta receptormediated ataxia telangiectasia mutated (ATM) kinase activation. J. Biol. Chem. 278:39527-39533.
15. Chen MR, Chang SJ, Huang H, Chen JY. 2000. A protein kinase activity associated with Epstein-Barr virus BGLF4 phosphorylates the viral early antigen EA-D in vitro. J. Virol. 74:3093-3104.
16. Chevallier-Greco A, et al. 1986. Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J. 5:3243-3249.
17. Chua HH, et al. 2012. p53 and Sp1 cooperate to regulate the expression of Epstein-Barr viral Zta protein. J. Med. Virol. 84:1279-1288.
18. Countryman J, Jenson H, Seibl R, Wolf H, Miller G. 1987. Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J. Virol. 61:3672-3679.
19. Countryman J, Miller G. 1985. Activation of expression of latent Epstein- Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc. Natl. Acad. Sci. U. S. A. 82: 4085-4089.
20. Darr CD, Mauser A, Kenney S. 2001. Epstein-Barr virus immediateearly protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. J. Virol. 75:6135-6142.
21. Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W. 1998. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc. Natl. Acad. Sci. U. S. A. 95:8245-8250.
22. Derheimer FA, Kastan MB. 2010. Multiple roles of ATM in monitoring and maintaining DNA integrity. FEBS Lett. 584:3675-3681.
23. Dickerson SJ, et al. 2009. Methylation-dependent binding of the Epstein-Barr virus BZLF1 protein to viral promoters. PLoS Pathog. 5:e1000356. doi:10.1371/journal.ppat.1000356.
24. Ellis AL, Wang Z, Yu X, Mertz JE. 2010. Either ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner. J. Virol. 84:6139-6152.
25. Fahmi H, Cochet C, Hmama Z, Opolon P, Joab I. 2000. Transforming growth factor beta 1 stimulates expression of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA by an indirect mechanism which requires the MAPK kinase pathway. J. Virol. 74:5810-5818.
26. Farrell PJ, Allan GJ, Shanahan F, Vousden KH, Crook T. 1991. p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J. 10:2879-2887.
27. Feederle R, et al. 2000. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J. 19:3080-3089.
28. Feng WH, Israel B, Raab-Traub N, Busson P, Kenney SC. 2002. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res. 62:1920-1926.
29. Feng WH, Kenney SC. 2006. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res. 66:8762-8769.
30. Forte E, Luftig MA. 2009. MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infectedcell survival. J. Virol. 83:2491-2499.
31. Gershburg E, Pagano JS. 2002. Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBVencoded protein kinase and effects of the L-riboside benzimidazole 1263W94. J. Virol. 76:998-1003.
32. Greenspan JS, et al. 1985. Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. N. Engl. J. Med. 313:1564-1571.
33. Gregory CD, Rowe M, Rickinson AB. 1990. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J. Gen. Virol. 71:1481-1495.
34. Gruffat H, Manet E, Rigolet A, Sergeant A. 1990. The enhancer factor R of Epstein-Barr virus (EBV) is a sequence-specific DNA binding protein. Nucleic Acids Res. 18:6835-6843.
35. Gruhne B, Sompallae R, Masucci MG. 2009. Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints. Oncogene 28:3997-4008.
36. Guo Z, Deshpande R, Paull TT. 2010. ATM activation in the presence of oxidative stress. Cell Cycle 9:4805-4811.
37. Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT. 2010. ATM activation by oxidative stress. Science 330:517-521.
38. Hagemeier SR, Barlow EA, Kleman AA, Kenney SC. 2011. The Epstein-Barr virus BRRF1 protein, Na, induces lytic infection in a TRAF2-and p53-dependent manner. J. Virol. 85:4318-4329.
39. Hardwick JM, Lieberman PM, Hayward SD. 1988. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J. Virol. 62:2274-2284.
40. Hickson I, et al. 2004. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 64:9152-9159.
41. Hoglund A, Nilsson LM, Forshell LP, Maclean KH, Nilsson JA. 2009. Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. Blood 113:4281-4288.
42. Hong GK, et al. 2004. The BRRF1 early gene of Epstein-Barr virus encodes a transcription factor that enhances induction of lytic infection by BRLF1. J. Virol. 78:4983-4992.
43. Hong YS, et al. 2012. Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1. Int. J. Oncol. 41:76-82.
44. Husaini R, Ahmad M, Soo-Beng Khoo A. 2011. Epstein-Barr virus latent membrane protein LMP1 reduces p53 protein levels independent of the PI3K-Akt pathway. BMC Res. Notes 4:551. doi:10.1186/1756-0500-4-551.
45. Ju R, Muller MT. 2003. Histone deacetylase inhibitors activate p21(WAF1) expression via ATM. Cancer Res. 63:2891-2897.
46. Kanda T, Yajima M, Ahsan N, Tanaka M, Takada K. 2004. Production of high-titer Epstein-Barr virus recombinants derived from Akata cells by using a bacterial artificial chromosome system. J. Virol. 78:7004-7015.
47. Kenney S, et al. 1989. The Epstein-Barr virus (EBV) BZLF1 immediateearly gene product differentially affects latent versus productive EBV promoters. J. Virol. 63:1729-1736.
48. Kieff E, Rickinson AB. 2007. Epstein-Barr virus and its replication, p 2603-2654. In Knipe DM, et al (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
49. Kim T, et al. 2011. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J. Exp. Med. 208:875-883.
50. Kudoh A, et al. 2005. Epstein-Barr virus lytic replication elicits ATM checkpoint signal transduction while providing an S-phase-like cellular environment. J. Biol. Chem. 280:8156-8163.
51. Laichalk LL, Thorley-Lawson DA. 2005. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J. Virol. 79:1296-1307.
52. Lassoued S, Gargouri B, El Feki Ael F, Attia H, Van Pelt J. 2010. Transcription of the Epstein-Barr virus lytic cycle activator BZLF-1 during oxidative stress induction. Biol. Trace Elem. Res. 137:13-22.
53. Lees-Miller SP, Sakaguchi K, Ullrich SJ, Appella E, Anderson CW. 1992. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol. Cell. Biol. 12:5041-5049.
54. Li R, et al. 2012. SUMO binding by the Epstein-Barr virus protein kinase BGLF4 is crucial for BGLF4 function. J. Virol. 86:5412-5421.
55. Li R, et al. 2011. Conserved herpesvirus kinases target the DNA damage response pathway and TIP60 histone acetyltransferase to promote virus replication. Cell Host Microbe 10:390-400.
56. Li X, Feng J, Sun R. 2011. Oxidative stress induces reactivation of Kaposi's sarcoma-associated herpesvirus and death of primary effusion lymphoma cells. J. Virol. 85:715-724.
57. Lieberman PM, Hardwick JM, Sample J, Hayward GS, Hayward SD. 1990. The zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions. J. Virol. 64:1143-1155.
58. Luka J, Kallin B, Klein G. 1979. Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 94:228-231.
59. Ma SD, et al. 2012. An Epstein-Barr virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. J. Virol. 86:7976-7987.
60. Maly FE, et al. 1988. The superoxide generating system of B cell lines. Structural homology with the phagocytic oxidase and triggering via surface Ig. J. Immunol. 140:2334-2339.
61. Maly FE, et al. 1989. Superoxide-dependent nitroblue tetrazolium reduction and expression of cytochrome b-245 components by human tonsillar B lymphocytes and B cell lines. J. Immunol. 142:1260-1267.
62. Masucci MG, et al. 1989. 5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line Rael. J. Virol. 63:3135-3141.
63. Matozaki T, et al. 1992. Missense mutations and a deletion of the p53 gene in human gastric cancer. Biochem. Biophys. Res. Commun. 182: 215-223.
64. Matsuoka S, et al. 2007. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316:1160-1166.
65. Mellinghoff I, et al. 1991. Early events in Epstein-Barr virus genome expression after activation: regulation by second messengers of B cell activation. Virology 185:922-928.
66. Meng Q, Hagemeier SR, Kuny CV, Kalejta RF, Kenney SC. 2010. Simian virus 40 T/t antigens and lamin A/C small interfering RNA rescue the phenotype of an Epstein-Barr virus protein kinase (BGLF4) mutant. J. Virol. 84:4524-4533.
67. Miller CL, Lee JH, Kieff E, Longnecker R. 1994. An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc. Natl. Acad. Sci. U. S. A. 91:772-776.
68. Miller CL, Longnecker R, Kieff E. 1993. Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes. J. Virol. 67:3087-3094.
69. Murata T, et al. 2009. TORC2, a coactivator of cAMP-response elementbinding protein, promotes Epstein-Barr virus reactivation from latency through interaction with viral BZLF1 protein. J. Biol. Chem. 284:8033-8041.
70. Nanbo A, Inoue K, Adachi-Takasawa K, Takada K. 2002. Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma. EMBO J. 21:954-965.
71. Neuhierl B, Feederle R, Hammerschmidt W, Delecluse HJ. 2002. Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection. Proc. Natl. Acad. Sci. U. S. A. 99:15036-15041.
72. Nikitin PA, et al. 2010. An ATM/Chk2-mediated DNA damageresponsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. Cell Host Microbe 8:510-522.
73. Nonkwelo C, Skinner J, Bell A, Rickinson A, Sample J. 1996. Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J. Virol. 70:623-627.
74. Prince S, et al. 2003. Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. J. Virol. 77:5000-5007.
75. Pujals A, et al. 2011. Treatment with a BH3 mimetic overcomes the resistance of latency III EBV (+) cells to p53-mediated apoptosis. Cell Death Dis. 2:e184. doi:10.1038/cddis.2011.67.
76. Ragoczy T, Heston L, Miller G. 1998. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J. Virol. 72:7978-7984.
77. Rickenson AB, Kieff E. 2007. Epstein-Barr virus, p 2655-2700. In Knipe DM, et al (ed), Fields virology, 5th ed. Lippincott Williams & Williams, Philadelphia, PA.
78. Robinson AR, Kwek SS, Hagemeier SR, Wille CK, Kenney SC. 2011. Cellular transcription factor Oct-1 interacts with the Epstein-Barr virus BRLF1 protein to promote disruption of viral latency. J. Virol. 85:8940-8953.
79. Robinson AR, Kwek SS, Kenney SC. 2012. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1. PLoS Pathog. 8:e1002516. doi: 10.1371/journal.ppat.1002516.
80. Rooney CM, Rowe DT, Ragot T, Farrell PJ. 1989. The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J. Virol. 63:3109-3116.
81. Rowe M, et al. 1995. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein- 1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur. J. Immunol. 25:1374-1384.
82. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101.
83. Schultz DC, Friedman JR, Rauscher FJ III. 2001. Targeting histone deacetylase complexes via KRAB-zinc finger proteins: the PHD and bromodomains of KAP-1 form a cooperative unit that recruits a novel isoform of the Mi-2alpha subunit of NuRD. Genes Dev. 15:428-443.
84. Shieh SY, Ikeda M, Taya Y, Prives C. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334.
85. Shirley CM, et al. 2011. Bortezomib induction of C/EBPbeta mediates Epstein-Barr virus lytic activation in Burkitt lymphoma. Blood 117: 6297-6303.
86. Siliciano JD, et al. 1997. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 11:3471-3481.
87. Smith J, Tho LM, Xu N, Gillespie DA. 2010. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv. Cancer Res. 108:73-112.
88. Takada K, Ono Y. 1989. Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J. Virol. 63:445-449.
89. Takada K, Shimizu N, Sakuma S, Ono Y. 1986. trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J. Virol. 57:1016-1022.
90. Tarakanova VL, et al. 2007. Gamma-herpesvirus kinase actively initiates a DNA damage response by inducing phosphorylation of H2AX to foster viral replication. Cell Host Microbe 1:275-286.
91. Tibbetts RS, et al. 1999. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 13:152-157.
92. Vassilev LT, et al. 2004. In vivo activation of the p53 pathway by smallmolecule antagonists of MDM2. Science 303:844-848.
93. Walling DM, Flaitz CM, Nichols CM, Hudnall SD, Adler-Storthz K. 2001. Persistent productive Epstein-Barr virus replication in normal epithelial cells in vivo. J. Infect. Dis. 184:1499-1507.
94. Webster-Cyriaque J, Middeldorp J, Raab-Traub N. 2000. Hairy leukoplakia: an unusual combination of transforming and permissive Epstein- Barr virus infections. J. Virol. 74:7610-7618.
95. Westphal EM, Blackstock W, Feng W, Israel B, Kenney SC. 2000. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res. 60:5781-5788.
96. Wiman KG, Magnusson KP, Ramqvist T, Klein G. 1991. Mutant p53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240. Oncogene 6:1633-1639.
97. Ye F, Lattif AA, Xie J, Weinberg A, Gao S. 2012. Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin- 2 in Kaposi sarcoma tumor cells. Cell Cycle 11:1393-1399.
98. Ye F, et al. 2011. Reactive oxygen species hydrogen peroxide mediates Kaposi's sarcoma-associated herpesvirus reactivation from latency. PLoS Pathog. 7:e1002054. doi:10.1371/journal.ppat.1002054.
99. Zalani S, Holley-Guthrie E, Kenney S. 1996. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cellspecific mechanism. Proc. Natl. Acad. Sci. U. S. A. 93:9194-9199.
100. Zhang S, et al. 2006. TGFbeta1-induced activation of ATM and p53 mediates apoptosis in a Smad7-dependent manner. Cell Cycle 5:2787-2795.
101. Zhang XP, Liu F, Wang W. 2011. Two-phase dynamics of p53 in the DNA damage response. Proc. Natl. Acad. Sci. U. S. A. 108:8990-8995.
102. zur Hausen H, et al. 1970. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228:1056-1058.